Barbaloin attenuates pulmonary fibrosis through TGF-β1/Smads/p38 pathway.

Gong ZhangRong BaiJianlin HuangYafeng GaoXiuli YunHaji Akber Aisa

Published in: The Journal of pharmacy and pharmacology (2022)

Our findings reveal the anti-pulmonary fibrosis effect of barbaloin in vivo and in vitro for the first time. These results indicate that barbaloin may be a promising clinical candidate drug against pulmonary fibrosis.

Keyphrases

pulmonary fibrosis
transforming growth factor
genome wide
gene expression
epithelial mesenchymal transition
drug induced
adverse drug